stockrow
Saturday 7 November 2026
Export RNAZ’s income statement to Excel — free account
TransCode Therapeutics Inc.
RNAZ Healthcare Biotechnology
- EPS
- −39.8%
- Free cash flow
- −28.8%
Quarter to June 2026, against a year earlier
1.51
0.00
0.00%
Follow RNAZ
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 1 | 1 | — | 0.0% | |
| Gross margin, % | — | — | — | — | — | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | — | (1) | (2) | (7) | (18) | (19) | (17) | (34) | (42) | +96.0% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | — | (1) | (2) | (7) | (18) | (19) | (17) | (35) | (43) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (0.94) | (0.51) | (0.81) | (998,419.10) | (95,783.52) | (1,320.45) | (52.59) | (50.65) | +95.6% | ||||||
| Cash flow | — | — | — | (0.79) | (0.11) | (0.63) | 0.00 | (90,372.50) | (1,058.41) | (28.30) | (23.62) | +81.6% | ||||||
| Capex | — | — | — | 0.00 | 0.00 | (0.03) | 0.00 | (178.00) | (1.73) | (0.01) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (0.79) | (0.11) | (0.65) | 0.00 | (90,550.50) | (1,060.14) | (28.31) | (23.62) | +81.6% | ||||||
| Book value | — | — | — | (1.70) | (0.74) | 2.42 | 0.00 | 8,204.00 | (160.21) | 14.99 | (28.93) | n/m | ||||||
| Shares, m | — | — | — | 1 | 5 | 8 | 0 | 0 | 0 | 1 | 1 | +1.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (1) | 0 | (5) | (16) | (18) | (13) | (20) | (23) | +83.7% | |||||
| Capex | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | (59.6%) | ||||||
| Free cash flow | — | — | — | (1) | 0 | (6) | (16) | (18) | (13) | (20) | (23) | +83.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 0 | 0 | 20 | 3 | 1 | 4 | 18 | 5 | +125.2% | |||||
| Net debt | — | — | — | 1 | 1 | (21) | (5) | (3) | (6) | (18) | (8) | n/m | ||||||
| Shareholders’ equity | — | — | — | (1) | (3) | 20 | 3 | 2 | (2) | 10 | (28) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (560.41) | (368.51) | (57.04) | (115.08) | (290.74) | (269.34) | (42.75) | (58.12) | +517.7 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 27.03 | 104.04 | (80.53) | (148.57) | (759.85) | 8,883.62 | (872.24) | 429.61 | (899.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 6 | 9 | 19 | 10 | 7 | 12 | — | +14.9% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
TransCode Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MGX Metagenomi Therapeutics, Inc. | $27.6M | — (loss-making) | — (loss-making) | −103.02% (below 0%: shrinking) | n/m | +7.98% (above 0%: growing) | 100.00% | 11,195.72% | Compare |
| PLRZ Polyrizon Ltd. | $27.5M | — | — | — | — | −744.51% (below 0%: shrinking) | — | — | Compare |
| ACET Adicet Bio, Inc. | $27.3M | — (loss-making) | — (loss-making) | +727.73% (above 0%: growing) | n/m | +24.94% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BYSI BeyondSpring Inc. | $26.0M | — (loss-making) | — (loss-making) | +87.78% (above 0%: growing) | n/m | +35.78% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ABVC ABVC BioPharma, Inc. | $25.9M | — (loss-making) | — (loss-making) | +66,233.33% (above 0%: growing) | n/m | +72.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| RNAZ TransCode Therapeutics Inc. | $25.6M | — (loss-making) | — | — | n/m | −28.79% (below 0%: shrinking) | 0.00% | 0.00% | |
| AARD Aardvark Therapeutics, Inc. | $24.3M | — (loss-making) | — | — | n/m | −77.14% (below 0%: shrinking) | — | 0.00% | Compare |
| CVM Cel-Sci Corporation | $24.1M | — (loss-making) | — (loss-making) | −62.66% (below 0%: shrinking) | n/m | −2.33% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CELU Celularity, Inc. | $23.5M | — (loss-making) | — (loss-making) | −5.30% (below 0%: shrinking) | n/m | −10.91% (below 0%: shrinking) | 56.79% | (78.00%) | Compare |
| Median of peers | $26.0M | — | — | +41.24% | — | +2.82% | 78.39% | 0.00% |
Pay and ownership Proxy statement filed 2 June 2026
Ownership
Directors and executive officers, together
less than 1%
Entities Associated with YA II PN, Ltd.
9.99%
Entities associated with CK Life Sciences Int’l., (Holdings) Inc.
9.90%
Entities associated with YA II PN, LTD
9.90%
Entities Associated with CK Life Sciences Int’l., (Holdings) Inc.
8.76%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement